The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors

Hazem Ghebeh, Shamayel Mohammed, Abeer Al-Omair, Amal Qattan, Cynthia Lehe, Ghofran Al-Qudaihi, Naser Elkum, Mohamed Alshabanah, Suad Bin Amer, Asma Tulbah, Dahish Ajarim, Taher Al-Tweigeri, Said Dermime Dermime

Research output: Contribution to journalArticle

388 Citations (Scopus)

Abstract

B7-H1 molecule increases the apoptosis of tumor-reactive T lymphocytes and reduces their immuno-genicity. Breast cancer is the second most common cause of mortality after lung cancer. Direct evidence linking B7-H1 with cancer has been shown in several malignancies; however, its expression in breast cancer has not been investigated. We used immunohistochemistry to investigate the expression of the B7-H1 molecule in 44 breast cancer specimens and to study its correlation with patients' clinicopathological parameters. The expression of B7-H1 was shown in 22 of 44 patients and was not restricted to the tumor epithelium (15 of 44, 34% in tumor cells), but was also expressed by tumor-infiltrating lymphocytes (TIL; 18 of 44, 41%). Interestingly, intratumor expression of B7-H1 was significantly associated with histologic grade III-negative (P = .012), estrogen receptor-negative (P = .036), and progesterone receptor-negative (P = .040) patients. In addition, the expression of B7-H1 in TIL was associated with large tumor size (P = .042), histologic grade III (P = .015), positivity of Her2/neu status (P = .019), and severe tumor lymphocyte infiltration (P = .001). Taken together, these data suggest that B7-H1 may be an important risk factor in breast cancer patients and may represent a potential immunotherapeutic target using monoclonal antibody against the B7-H1 molecule.

Original languageEnglish
Pages (from-to)190-198
Number of pages9
JournalNeoplasia
Volume8
Issue number3
DOIs
Publication statusPublished - Mar 2006
Externally publishedYes

    Fingerprint

Keywords

  • B7-H1
  • Breast cancer
  • PD-L1
  • Prognostic factors
  • Tumor-infiltrating lymphocytes

ASJC Scopus subject areas

  • Cancer Research

Cite this

Ghebeh, H., Mohammed, S., Al-Omair, A., Qattan, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Amer, S. B., Tulbah, A., Ajarim, D., Al-Tweigeri, T., & Dermime, S. D. (2006). The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors. Neoplasia, 8(3), 190-198. https://doi.org/10.1593/neo.05733